2025
Zennami K, Graham M, Chikara S, Sysa-Shah P, Rafiqi FH, Wang R, Abel B, Zeng Q, Krueger TEG, Brennen WN, Ganguly S, Zarif JC, Simons B, DeWeese TL, De Marzo A, Yegnasubramanian S, Lupold SE. bioRxiv [preprint]. Cell Type-Specific Effects of miR-21 Loss Attenuate Tumor Progression in MYC-Driven Prostate Cancer. 2025 May 18: 2025.05.14.654101. doi: 10.1101/2025.05.14.654101. PMID: 40463282.
Caramella-Pereira F, Zheng Q, Hicks JL, Roy S, Jones T, Pomper M, Antony L, Meeker AK, Yegnasubramanian S, De Marzo AM, Brennen WN. Overexpression of Fibroblast Activation Protein (FAP) in stroma of proliferative inflammatory atrophy (PIA) and primary adenocarcinoma of the prostate. Pathology. 2025 Mar 1: S0031-3025(25)00093-5; 2025. doi: 10.1016/j.pathol.2024.12.637. PMID: 40187966.
2024
Nouri M, Varkaris A, Ridinger M, Dalrymple SL, Dennehy CM, Isaacs JT, Einstein DJ, Brennen WN, Balk SP. Mol Cancer Ther. AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer. 2024 Oct 1; 23(10): 1404-1417. doi: 10.1158/1535-7163.MCT-23-0933. PMID: 38894678.
Caramella-Pereira F, Zheng Q, Hicks JL, Roy S, Jones T, Pomper M, Antony L, Meeker AK, Yegnasubramanian S, De Marzo AM, Brennen WN. Overexpression of Fibroblast Activation Protein (FAP) in stroma of proliferative inflammatory atrophy (PIA) and primary adenocarcinoma of the prostate. medRxiv [Preprint]. 2024 Apr 5:2024.04.04.24305338. doi: 10.1101/2024.04.04.24305338. PMID: 38633791.
Jasmine S, Mandl A, Krueger TEG, Dalrymple SL, Antony L, Dias J, Celatka CA, Tapper AE, Kleppe M, Kanayama M, Jing Y, Speranzini V, Wang YZ, Luo J, Trock BJ, Denmeade SR, Carducci MA, Mattevi A, Rienhoff HY Jr, Isaacs JT, Brennen WN. Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models. Prostate. 2024 Jul;84(10):909-921. doi: 10.1002/pros.24707. Epub 2024 Apr 15. PMID: 38619005.
Pacheco-Torres J, Sharma RK, Mironchik Y, Wildes F, Brennen WN, Artemov D, Krishnamachary B, Bhujwalla ZM. Prostate fibroblasts and prostate cancer associated fibroblasts exhibit different metabolic, matrix degradation and PD-L1 expression responses to hypoxia. Front Mol Biosci. 2024 Mar 22;11:1354076. doi: 10.3389/fmolb.2024.1354076. eCollection 2024. PMID: 38584702.
Stangis MM, Chen Z, Min J, Glass SE, Jackson JO, Radyk MD, Hoi XP, Brennen WN, Yu M, Dinh HQ, Coffey RJ, Shrubsole MJ, Chan KS, Grady WM, Yegnasubramanian S, Lyssiotis CA, Maitra A, Halberg RB, Dey N, Lau KS. The Hallmarks of Precancer. Cancer Discov. 2024 Apr 4;14(4):683-689. doi: 10.1158/2159-8290.CD-23-1550. PMID: 38571435
Brennen WN, Le Magnen C, Karkampouna S, Anselmino N, Bock N, Choo N, Clark AK, Coleman IM, Dolgos R, Ferguson AM, Goode DL, Krutihof-de Julio M, Navone NM, Nelson PS, O’Neill E, Porter LH, Ranasinghe W, Sunada T, Williams ED, Butler LM, Corey E, van Weerden WM, Taylor RA, Risbridger GP, Lawrence MG. Defining the challenges and opportunities for using patient-derived models in prostate cancer research. Prostate. 2024 May;84(7):623-635. doi: 10.1002/pros.24682. Epub 2024 Mar 7. PMID: 38450798.
Mandl A, Jasmine S, Krueger T, Kumar R, Coleman IM, Dalrymple SL, Antony L, Rosen DM, Jing Y, Hanratty B, Patel RA, Jin-Yih L, Dias J, Celatka CA, Tapper AE, Kleppe M, Kanayama M, Speranzini V, Wang YZ, Luo J, Corey E, Sena LA, Casero RA, Lotan T, Trock BJ, Kachhap SK, Denmeade SR, Carducci MA, Mattevi A, Haffner MC, Nelson PS, Rienhoff HY, Isaacs JT, Brennen WN. LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancer. bioRxiv. 2024 Jan 22. doi: 10.1101/2024.01.17.576106. PMID: 38328141.
Mori JO, Elhussin I, Brennen WN, Graham MK, Lotan TL, Yates CC, De Marzo AM, Denmeade SR, Yegnasubramanian S, Nelson WG, Denis GV, Platz EA, Meeker AK, Heaphy CM. Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer. Nat Rev Urol. 2024 May; 21(5): 258-273. doi: 10.1038/s41585-023-00827-x. Epub 2023 Oct 31. PMID: 37907729.
Patel RA, Sayar E, Coleman I, Roudier MP, Hanratty B, Low JY, Jaiswal N, Ajkunic A, Dumpit R, Ercan C, Salama N, O’Brien VP, Isaacs WB, Epstein JI, De Marzo AM, Trock BJ, Luo J, Brennen WN, Tretiakova M, Vakar-Lopez F, True LD, Goodrich DW, Corey E, Morrissey C, Nelson PS, Hurley PJ, Gulati R, Haffner MC. Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer. J Pathol. 2024 Jan;262(1):105-120. doi: 10.1002/path.6216. Epub 2023 Oct 18. PMID: 37850574.
Labrecque MP, Brown LG, Coleman IM, Nguyen HM, Dalrymple S, Brennen WN, Isaacs JT, Li D, Lakely B, DeLucia DC, Lee JK, Schweizer MT, Lin DW, Corey E, Nelson PS, Morrissey C. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer. Prostate. 2024 Jan;84(1):100-110. doi: 10.1002/pros.24630. Epub 2023 Oct 5. PMID: 37796107.
2023
Isaacs JT, Dalrymple SL, Antony L, Marc Rosen D, Coleman IM, Nelson PS, Kostova M, Murray IA, Perdew GH, Denmeade SR, Akinboye ES, Brennen WN. Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1a, and MEF-2 signaling for metastatic castration-resistant prostate cancer. Prostate. 2023 Nov;83(15):1470-1493. doi: 10.1002/pros.24606. Epub 2023 Aug 9. PMID: 37559436.
Pruitt HC, Guan Y, Liu H, Carey AE, Brennen WN, Lu J, Joshu C, Weeraratna A, Lotan TL, Karin Eisinger-Mathason TS, Gerecht S. Collagen VI deposition mediates stromal T cell trapping through inhibition of T cell motility in the prostate tumor microenvironment. Matrix Biol. 2023 Aug;121:90-104. doi: 10.1016/j.matbio.2023.06.002. Epub 2023 Jun 16. PubMed PMID: 37331435.
Lu P, Oetjen KA, Bender DE, Ruzinova MB, Fisher DAC, Shim KG, Pachynski RK, Brennen WN, Oh ST, Link DC, Thorek DLJ. IMC-Denoise: a content aware denoising pipeline to enhance Imaging Mass Cytometry. Nat Commun. 2023 Mar 23;14(1):1601. doi: 10.1038/s41467-023-37123-6. PubMed PMID: 36959190.
2022
Sena LA, Kumar R, Sanin DE, Thompson EA, Rosen DM, Dalrymple SL, Antony L, Yang Y, Gomes-Alexandre C, Hicks JL, Jones T, Bowers KA, Eskra JN, Meyers J, Gupta A, Skaist A, Yegnasubramanian S, Luo J, Brennen WN, Kachhap SK, Antonarakis ES, De Marzo AM, Isaacs JT, Markowski MC, Denmeade SR. Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC. J Clin Invest. 2022 Dec 1;132(23). doi: 10.1172/JCI162396. PMID: 36194476.
de Groot AE, Myers KV, Krueger TEG, Brennen WN, Amend SR, Pienta KJ. Targeting interleukin 4 receptor alpha on tumor-associated macrophages reduces the pro-tumor macrophage phenotype. Neoplasia. 2022 Oct;32:100830. doi: 10.1016/j.neo.2022.100830. Epub 2022 Aug 5. PMID: 35939881.
Sena LA, Brennen WN, Isaacs JT. There are gremlins in prostate cancer. Nat Cancer. 2022 May;3(5):530-531. doi: 10.1038/s43018-022-00381-2. PMID: 35624340.
2021
Isaacs JT, Brennen WN, Christensen SB, Denmeade SR. Mipsagargin: The Beginning-Not the End-of Thapsigargin Prodrug-Based Cancer Therapeutics. Molecules. 2021 Dec 9;26(24). doi: 10.3390/molecules26247469. PMID: 34946547.
Kumar R, Mendonca J, Owoyemi O, Boyapati K, Thomas N, Kanacharoen S, Coffey M, Topiwala D, Gomes C, Ozbek B, Jones T, Rosen M, Dong L, Wiens S, Brennen WN, Isaacs JT, De Marzo AM, Markowski MC, Antonarakis ES, Qian DZ, Pienta KJ, Pardoll DM, Carducci MA, Denmeade SR, Kachhap SK. Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer. Cancer Res. 2021 Dec 1;81(23):5948-5962. doi: 10.1158/0008-5472.CAN-20-3607. Epub 2021 Oct 13. PMID: 34645612.
de Groot AE, Myers KV, Krueger TEG, Kiemen AL, Nagy NH, Brame A, Torres VE, Zhang Z, Trabzonlu L, Brennen WN, Wirtz D, De Marzo AM, Amend SR, Pienta KJ. Characterization of tumor-associated macrophages in prostate cancer transgenic mouse models. Prostate. 2021 Jul;81(10):629-647. doi: 10.1002/pros.24139. Epub 2021 May 5. PMID: 33949714.
Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Correction: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene. 2021 Jun;40(22):3914-3916. doi: 10.1038/s41388-021-01805-6. PMID: 33958727.
Brennen WN, Zhu Y, Coleman IM, Dalrymple SL, Antony L, Patel RA, Hanratty B, Chikarmane R, Meeker AK, Zheng SL, Hooper JE, Luo J, De Marzo AM, Corey E, Xu J, Yegnasubramanian S, Haffner MC, Nelson PS, Nelson WG, Isaacs WB, Isaacs JT. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. JCI Insight. 2021 Apr 22;6(8). doi: 10.1172/jci.insight.146827. PubMed PMID: 33724955.
Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Correction to: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene. 2021 Mar;40(11):2148. doi: 10.1038/s41388-021-01640-9. PMID: 33564077.
Brennen WN, J Thorek DL, Jiang W, Krueger TE, Antony L, Denmeade SR, Isaacs JT. Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy. Immunotherapy. 2021 Feb;13(2):155-175. doi: 10.2217/imt-2020-0066. Epub 2020 Nov 5. PMID: 33148078.
2020
Eskra JN, Rabizadeh D, Mangold L, Fabian E, Brennen WN, Yeater DB, Pienta KJ, Partin AW, Isaacs WB, Pavlovich CP, Luo J. A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization. Prostate Cancer Prostatic Dis. 2021 Mar;24(1):220-232. doi: 10.1038/s41391-020-00272-6. Epub 2020 Aug 20. PMID: 32820256.
Rogers OC, Antony L, Levy O, Joshi N, Simons BW, Dalrymple SL, Rosen DM, Pickering A, Lan H, Kuang H, Ranganath SH, Zheng L, Karp JM, Howard SP, Denmeade SR, Isaacs JT, Brennen WN. Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer. Mol Cancer Ther. 2020 Nov;19(11):2353-2362. doi: 10.1158/1535-7163.MCT-20-0227. Epub 2020 Sep 17. PMID: 32943549.
Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene. 2020 Nov;39(45):6935-6949. doi: 10.1038/s41388-020-01479-6. Epub 2020 Sep 28. PMID: 32989253.
Simons BW, Dalrymple S, Rosen M, Zheng L, Brennen WN. A hemi-spleen injection model of liver metastasis for prostate cancer. Prostate. 2020 Oct;80(14):1263-1269. doi: 10.1002/pros.24055. Epub 2020 Aug 6. PMID: 32761950.
Low JY, Brennen WN, Meeker AK, Ikonen E, Simons BW, Laiho M. Stromal CAVIN1 Controls Prostate Cancer Microenvironment and Metastasis by Modulating Lipid Distribution and Inflammatory Signaling. Mol Cancer Res. 2020 Sep;18(9):1414-1426. doi: 10.1158/1541-7786.MCR-20-0364. Epub 2020 Jun 3. PMID: 32493699.
2019
Isaacs JT, Brennen WN, Denmeade SR. Serial bipolar androgen therapy (sBAT) using cyclic supraphysiologic testosterone (STP) to treat metastatic castration-resistant prostate cancer (mCRPC). Ann Transl Med. 2019 Dec;7(Suppl 8):S311. doi: 10.21037/atm.2019.10.32. PMID: 32016030.
Hughes RM, Simons BW, Khan H, Miller R, Kugler V, Torquato S, Theodros D, Haffner MC, Lotan T, Huang J, Davicioni E, An SS, Riddle RC, Thorek DLJ, Garraway IP, Fertig EJ, Isaacs JT, Brennen WN, Park BH, Hurley PJ. Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression. Cancer Res. 2019 Jul 15;79(14):3636-3650. doi: 10.1158/0008-5472.CAN-18-2931. Epub 2019 May 23. PMID: 31123087.
Brennen WN, Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Denmeade SR. In Reply. Stem Cells Transl Med. 2019 Jul;8(7):739-740. doi: 10.1002/sctm.19-0068. Epub 2019 Mar 29. PMID: 30925030.
Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Brennen WN, Denmeade SR. A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer. Stem Cells Transl Med. 2019 May;8(5):441-449. doi: 10.1002/sctm.18-0230. Epub 2019 Feb 8. PMID: 30735000.
Krueger TE, Thorek DLJ, Meeker AK, Isaacs JT, Brennen WN. Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?. Prostate. 2019 Feb;79(3):320-330. doi: 10.1002/pros.23738. Epub 2018 Nov 28. PMID: 30488530.
2018
Akinboye ES, Brennen WN, Denmeade SR, Isaacs JT. Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer. Asian J Urol. 2019 Jan;6(1):99-108. doi: 10.1016/j.ajur.2018.11.004. Epub 2018 Nov 28. PMID: 30775253.
Navone NM, van Weerden WM, Vessella RL, Williams ED, Wang Y, Isaacs JT, Nguyen HM, Culig Z, van der Pluijm G, Rentsch CA, Marques RB, de Ridder CMA, Bubendorf L, Thalmann GN, Brennen WN, Santer FR, Moser PL, Shepherd P, Efstathiou E, Xue H, Lin D, Buijs J, Bosse T, Collins A, Maitland N, Buzza M, Kouspou M, Achtman A, Taylor RA, Risbridger G, Corey E. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. Prostate. 2018 Dec;78(16):1262-1282. doi: 10.1002/pros.23701. Epub 2018 Aug 2. PMID: 30073676.
Brennen WN, Isaacs JT. Mesenchymal stem cells and the embryonic reawakening theory of BPH. Nat Rev Urol. 2018 Nov;15(11):703-715. doi: 10.1038/s41585-018-0087-9. PMID: 30214054.
Krueger TEG, Thorek DLJ, Denmeade SR, Isaacs JT, Brennen WN. Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med. 2018 Sep;7(9):651-663. doi: 10.1002/sctm.18-0024. Epub 2018 Aug 1. PMID: 30070053.
Kostova MB, Brennen WN, Lopez D, Anthony L, Wang H, Platz E, Denmeade SR. PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones. Prostate. 2018 Aug;78(11):819-829. doi: 10.1002/pros.23539. Epub 2018 Apr 16. PMID: 29659051.
Brennen WN, Isaacs JT. The what, when, and why of human prostate cancer xenografts. Prostate. 2018 Jun;78(9):646-654. doi: 10.1002/pros.23510. Epub 2018 Mar 24. PMID: 29575112.
Kumar B, Rosenberg AZ, Choi SM, Fox-Talbot K, De Marzo AM, Nonn L, Brennen WN, Marchionni L, Halushka MK, Lupold SE. Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer. Sci Rep. 2018 May 8;8(1):7189. doi: 10.1038/s41598-018-25320-z. PMID: 29739972.
Rogers OC, Anthony L, Rosen DM, Brennen WN, Denmeade SR. PSA-selective activation of cytotoxic human serine proteases within the tumor microenvironment as a therapeutic strategy to target prostate cancer. Oncotarget. 2018 Apr 27;9(32):22436-22450. doi: 10.18632/oncotarget.25091. eCollection 2018 Apr 27. PMID: 29854290.
2017
Brennen WN, Isaacs JT. Cellular Origin of Androgen Receptor Pathway-Independent Prostate Cancer and Implications for Therapy. Cancer Cell. 2017 Oct 9;32(4):399-401. doi: 10.1016/j.ccell.2017.09.011. PMID: 29017052.
Isaacs JT, Brennen WN, Denmeade SR. Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancer. Cell Cycle. 2017 Sep 17;16(18):1639-1640. doi: 10.1080/15384101.2017.1360645. Epub 2017 Aug 18. PMID: 28820291.
Brennen WN, Zhang B, Kulac I, Kisteman LN, Antony L, Wang H, Meeker AK, De Marzo AM, Garraway IP, Denmeade SR, Isaacs JT. Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate. Oncotarget. 2017 Jul 18;8(29):46710-46727. doi: 10.18632/oncotarget.17362. PMID: 28493842.
2016
Brennen WN, Nguyen H, Dalrymple SL, Reppert-Gerber S, Kim J, Isaacs JT, Hammers H. Assessing angiogenic responses induced by primary human prostate stromal cells in a three-dimensional fibrin matrix assay. Oncotarget. 2016 Nov 1;7(44):71298-71308. doi: 10.18632/oncotarget.11347. PMID: 27542256.
Levy O, Brennen WN, Han E, Rosen DM, Musabeyezu J, Safaee H, Ranganath S, Ngai J, Heinelt M, Milton Y, Wang H, Bhagchandani SH, Joshi N, Bhowmick N, Denmeade SR, Isaacs JT, Karp JM. A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. Biomaterials. 2016 Jun;91:140-150. doi: 10.1016/j.biomaterials.2016.03.023. Epub 2016 Mar 17. PMID: 27019026.
Akinboye ES, Brennen WN, Rosen DM, Bakare O, Denmeade SR. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy. Prostate. 2016 Jun;76(8):703-14. doi: 10.1002/pros.23162. Epub 2016 Feb 2. PMID: 26835873.
Brennen WN, Kisteman LN, Isaacs JT. Rapid selection of mesenchymal stem and progenitor cells in primary prostate stromal cultures. Prostate. 2016 May;76(6):552-64. doi: 10.1002/pros.23145. Epub 2016 Jan 6. PMID: 26732992.
2015 – 2005
Miles LA, Brennen WN, Rudin CM, Poirier JT. Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug Therapy. PLoS One. 2015;10(6):e0129103. doi: 10.1371/journal.pone.0129103. eCollection 2015. PubMed PMID: 26069962.
Brennen WN, Rosen DM, Chaux A, Netto GJ, Isaacs JT, Denmeade SR. Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer. Prostate. 2014 Sep;74(13):1308-19. doi: 10.1002/pros.22847. Epub 2014 Jul 22. PMID: 25053236.
Brennen WN, Drake CG, Isaacs JT. Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancer. Cancer Res. 2014 Jul 1;74(13):3390-5. doi: 10.1158/0008-5472.CAN-14-0249. Epub 2014 Apr 18. PMID: 24747912.
Brennen WN, Denmeade SR, Isaacs JT. Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr Relat Cancer. 2013 Oct;20(5):R269-90. doi: 10.1530/ERC-13-0151. Print 2013 Oct. PMID: 23975882.
Isaacs JT, Antony L, Dalrymple SL, Brennen WN, Gerber S, Hammers H, Wissing M, Kachhap S, Luo J, Xing L, Björk P, Olsson A, Björk A, Leanderson T. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res. 2013 Feb 15;73(4):1386-99. doi: 10.1158/0008-5472.CAN-12-2730. Epub 2012 Nov 13. PMID: 23149916.
Brennen WN, Chen S, Denmeade SR, Isaacs JT. Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer. Oncotarget. 2013 Jan;4(1):106-17. doi: 10.18632/oncotarget.805. PMID: 23362217.
Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. J Natl Cancer Inst. 2012 Sep 5;104(17):1320-34. doi: 10.1093/jnci/djs336. Epub 2012 Aug 21. PMID: 22911669.
Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, Isaacs JT. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med. 2012 Jun 27;4(140):140ra86. doi: 10.1126/scitranslmed.3003886. PMID: 22745436.
Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther. 2012 Feb;11(2):257-66. doi: 10.1158/1535-7163.MCT-11-0340. PMID: 22323494.
Lin J, Haffner MC, Zhang Y, Lee BH, Brennen WN, Britton J, Kachhap SK, Shim JS, Liu JO, Nelson WG, Yegnasubramanian S, Carducci MA. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate. 2011 Mar 1;71(4):333-43. doi: 10.1002/pros.21247. Epub 2010 Aug 31. PMID: 20809552.
LeBeau AM, Brennen WN, Aggarwal S, Denmeade SR. Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Mol Cancer Ther. 2009 May;8(5):1378-86. doi: 10.1158/1535-7163.MCT-08-1170. Epub 2009 May 5. PMID: 19417147.
Aggarwal S, Brennen WN, Kole TP, Schneider E, Topaloglu O, Yates M, Cotter RJ, Denmeade SR. Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry. 2008 Jan 22;47(3):1076-86. doi: 10.1021/bi701921b. Epub 2007 Dec 21. PMID: 18095711.
Brennen WN, Cooper CR, Capitosti S, Brown ML, Sikes RA. Thalidomide and analogues: current proposed mechanisms and therapeutic usage. Clin Prostate Cancer. 2004 Jun;3(1):54-61. doi: 10.3816/cgc.2004.n.014. PMID: 15279692.
Sikes RA, Walls AM, Brennen WN, Anderson JD, Choudhury-Mukherjee I, Schenck HA, Brown ML. Therapeutic approaches targeting prostate cancer progression using novel voltage-gated ion channel. Clin Prostate Cancer. 2003 Dec; 2(3): 181-187. doi: 10.3816/cgc.2003.n.028. PMID: 15040863.
